Inactive Instrument

Acacia Pharma Group plc Share Price

ACPH

GB00BYWF9Y76

Latest news about Acacia Pharma Group plc

Eagle Pharmaceuticals Completes Acacia Pharma Acquisition	09/06/22	MT
Acacia Pharma's Acquisition by Eagle Pharmaceuticals Closes; Shares Delist	09/06/22	MT
Acacia Pharma Group plc(ENXTBR:ACPH) dropped from Next Biotech Index	08/06/22	CI
Acacia Pharma's Acquisition by Eagle Pharmaceuticals Nears Completion	07/06/22	MT
Eagle Pharmaceuticals, Inc. completed the acquisition of Acacia Pharma Group plc from a group of shareholders.	05/06/22	CI
Acacia Pharma Group plc Auditor Raises 'Going Concern' Doubt	28/04/22	CI
Acacia Pharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2021	28/04/22	CI
Sector Update: Health Care Stocks Posting Modest Gains Monday	28/03/22	MT
Health Care Up on Revival of Demand for Growth Sectors -- Health Care Roundup	28/03/22	DJ
Sector Update: Health Care Stocks Still Looking for Monday Direction	28/03/22	MT
Sector Update: Health Care	28/03/22	MT
FTSE 100 Closes Lower Despite Earlier Hopes on Russia, Ukraine Talks	28/03/22	DJ
FTSE 100 Rises, 10Y Gilt Yields Hit Six-Year High as Interest-Rate Rises Loom	28/03/22	DJ
FTSE Rises, Rolls-Royce Slides as Takeover Talk Remains Unconfirmed	28/03/22	DJ
FTSE 100 Rises on Optimism Over Russia-Ukraine Talks	28/03/22	DJ

More news

Analyst Recommendations on Acacia Pharma Group plc

FTSE 100 Rises, 10Y Gilt Yields Hit Six-Year High as Interest-Rate Rises Loom	28/03/22	DJ
ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot, Wizz Air...	01/10/21

More recommendations

Press releases Acacia Pharma Group plc

Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint	09/06/22	AQ
Scheme of arrangement becoming effective	09/06/22	GL
Scheme of arrangement becoming effective	09/06/22	AQ
Court Sanction of the Scheme of Arrangement	07/06/22	GL
Court Sanction of the Scheme of Arrangement	07/06/22	AQ

More press releases

News in other languages on Acacia Pharma Group plc

Bel20 beperkt zijn verliezen bij het slot	07/06/22
Brussel in het rood	07/06/22
Overname Acacia afgerond	07/06/22
Bel20 sluit week hoger af	20/05/22
Brussel omhoog	20/05/22

More news

Managers and Directors - Acacia Pharma Group plc

Managers	Title	Age	Since
Michael Bolinder CEO	Chief Executive Officer	-	31/07/15
Scott A. Byrd CHM	Chairman	54	28/02/15
Gabriel Fox CTO	Chief Tech/Sci/R&D Officer	-	31/12/07

Members of the board	Title	Age	Since
Ed Borkowski BRD	Director/Board Member	64	28/02/18
John Brown BRD	Director/Board Member	69	28/02/18
Scott A. Byrd CHM	Chairman	54	28/02/15

More insiders

Acacia Pharma Group plc specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2021, the group had a portfolio of 3 products, including 1 in phase II of clinical development (APD403; treatment of chemically induced nausea and vomiting) and 2 in pre-launch phase: BARHEMSYS (treatment of nausea and postoperative vomiting) and BYFAVO (benzodiazepine sedative for use in invasive medical procedures in adults, such as colonoscopy and bronchoscopy).

Sector

More about the company